ADAG · Adagene Inc.

This $70.0 million public offering represents a significant capital-raising event for Adagene, a clinical-stage biotechnology company advancing antibody-based cancer immunotherapies. The offering is structured as an underwritten sale of 18,666,000 ADSs — each representing 1.25 ordinary shares — resulting in the issuance of 23,332,500 new ordinary shares. Priced at $3.75 per ADS (the 30-day VWAP), the transaction is executed under an effective Form F-3 shelf registration, signaling regulatory readiness and operational efficiency in accessing U.S. capital markets. The involvement of Leerink Partners and LifeSci Capital — both specialized in life sciences financings — underscores market confidence in Adagene’s platform, particularly its SAFEbody precision masking technology and AI-driven antibody discovery engine. Proceeds are designated for general corporate purposes, explicitly including R&D and clinical trials, which aligns with Adagene’s current phase of advancing novel immunotherapies through clinical development. Given Adagene’s status as a pre-revenue, clinical-stage biotech with no commercial products, this financing is essential to sustain operations, advance pipeline candidates, and maintain strategic flexibility. The timing — immediately following the filing of its 2025 Annual Report on Form 20-F — suggests proactive liquidity management ahead of anticipated clinical milestones or data readouts. As a dilutive equity event, it materially impacts existing shareholders’ ownership and warrants close monitoring of subsequent cash burn and pipeline progress.